Form 4: Shanmugam Muthusamy reports disposition transactions in ANIP

Rhea-AI Filing Summary

Shanmugam Muthusamy reported disposition transactions in a Form 4 filing for ANIP. The filing lists transactions totaling 2,898 shares at a weighted average price of $76.25 per share. Following the reported transactions, holdings were 89,940 shares.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Shanmugam Muthusamy

Role HEAD OF R&D, COO-NOVITIUM OPS

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	2,898	$76.25	$221K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 89,940 shares (Direct); Common Stock — 431,920 shares (Indirect, Held by Esjay LLC)

Footnotes (1)

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 11,578 performance stock units, the grant of which was previously reported on April 6, 2023. Includes 250 shares of ANI Pharmaceuticals, Inc. Common Stock that were acquired under the ANI Pharmaceuticals, Inc. Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c). The reporting person holds voting and dispositive power over the shares held by Esjay LLC. The reporting person holds voting and dispositive power over the shares held by SS Pharma LLC.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shanmugam Muthusamy

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	HEAD OF R&D, COO-NOVITIUM OPS

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		F		2,898(1)	D	$76.25	89,940(2)	D
Common Stock								431,920	I	Held by Esjay LLC(3)
Common Stock								5,000	I	Held by SS Pharma LLC(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 11,578 performance stock units, the grant of which was previously reported on April 6, 2023.

2. Includes 250 shares of ANI Pharmaceuticals, Inc. Common Stock that were acquired under the ANI Pharmaceuticals, Inc. Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c).

3. The reporting person holds voting and dispositive power over the shares held by Esjay LLC.

4. The reporting person holds voting and dispositive power over the shares held by SS Pharma LLC.

Remarks:

	/s/ Muthusamy Shanmugam, by attorney-in-fact Meredith W. Cook	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ANI Pharmaceuticals (ANIP) report on February 11, 2026?

ANI Pharmaceuticals reported a tax-withholding disposition of 2,898 common shares on February 11, 2026. The shares were withheld to cover taxes due upon vesting of 11,578 performance stock units previously granted in April 2023.

Who is the insider in the ANI Pharmaceuticals (ANIP) February 2026 Form 4 filing?

The insider is Shanmugam Muthusamy, a director and officer of ANI Pharmaceuticals serving as Head of R&D and COO-Novitium Ops. The filing details his tax-related share disposition and updated direct and indirect beneficial ownership positions.

How many ANI Pharmaceuticals (ANIP) shares does Shanmugam Muthusamy own directly after the transaction?

After the reported tax-withholding transaction, Shanmugam Muthusamy directly beneficially owns 89,940 shares of ANI Pharmaceuticals common stock. This figure reflects his holdings following the disposition of 2,898 shares to satisfy tax obligations from performance stock unit vesting.

What indirect ANI Pharmaceuticals (ANIP) holdings are reported for Shanmugam Muthusamy?

The Form 4 shows 431,920 ANI Pharmaceuticals common shares held by Esjay LLC and 5,000 shares held by SS Pharma LLC. Footnotes state Muthusamy holds voting and dispositive power over both entities’ shares, making them indirect beneficial holdings.

Was the ANI Pharmaceuticals (ANIP) insider transaction an open-market sale?

No, the transaction was a tax-withholding disposition coded “F,” not an open-market sale. Shares were withheld to pay tax obligations arising from the vesting of 11,578 performance stock units, under Rule 16b-3 exemptions for such equity compensation events.

What equity award vesting triggered the ANI Pharmaceuticals (ANIP) tax withholding?

The tax withholding was triggered by the vesting of 11,578 performance stock units granted to Shanmugam Muthusamy. The grant was previously reported on April 6, 2023, and the February 11, 2026 Form 4 records shares withheld for associated tax obligations.